ARTICLE | Clinical News
ACTOplus met pioglitazone/metformin: Phase III data
October 26, 2009 7:00 AM UTC
A double-blind, Phase III trial in 600 Type II diabetes patients showed that twice-daily ACTOplus met (15 mg Actos pioglitazone/850 mg metformin) met the primary endpoint of a significant decrease from baseline in HbA1c compared with either monotherapy (1.83% vs. 0.99% for Actos and 0.64% for metformin, p<0.001 for each). A larger proportion of patients receiving ACTOplus met (64%) achieved HbA1c <7% than either Actos (46%) or metformin (39%) alone. ...